High Doses of Topical Amitriptyline in Neuropathic Pain: Two Cases and Literature Review

Pain Practice

Volumn 12, Issue 2, 2012, Pages 148-153

  Kopsky, David J ^a   Keppel Hesselink, Jan M ^a  

^a Institute for Neuropathic Pain   (Netherlands)

Author keywords

Amitriptyline; Axonal neuropathy; Chronic idiopathic axonal neuropathy; Cream; Diabetic neuropathy; Neuropathic pain; Peripheral neuropathies; Polyneuropathy; Topical

Indexed keywords

AMITRIPTYLINE; FENTANYL; KETAMINE; LIDOCAINE; NALTREXONE; PREGABALIN; TILIDINE;

ADULT; ARTICLE; CASE REPORT; CONCENTRATION LOSS; DROWSINESS; DRUG BLOOD LEVEL; ELECTROMYOGRAM; FOOT; HAND; HUMAN; MALE; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PATIENT SATISFACTION; POLYNEUROPATHY; QUESTIONNAIRE; SCORING SYSTEM; SENSORY DYSFUNCTION; SIDE EFFECT; THINKING; TREATMENT RESPONSE;

EID: 84856585541     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00477.x     Document Type: Article

References (48)

1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-1522.
2. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982.
3. Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137:681-688.
4. Erdmann PG, van Genderen FR, Teunissen LL, et al. Pain in patients with chronic idiopathic axonal polyneuropathy. Eur Neurol. 2010;64:58-64.
5. Vrancken AF, van Schaik IN, Hughes RA, Notermans NC. Drug therapy for chronic idiopathic axonal polyneuropathy. Cochrane Database Syst Rev. 2004;2:CD003456.
6. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3-S14.
7. Ziegler D. Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care. 2009;32:S414-S419.
8. Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother. 2005;5:823-830.
9. Tadicherla S, Berman B. Percutaneous dermal drug delivery for local pain control. Ther Clin Risk Manag. 2006;2:99-113.
10. Strumper D, Durieux ME. Antidepressants as long-acting local anesthetics. Reg Anesth Pain Med. 2004;29:277-285.
11. Oatway M, Reid A, Sawynok J. Peripheral antihyperalgesic and analgesic actions of ketamine and amitriptyline in a model of mild thermal injury in the rat. Anesth Analg. 2003;97:168-173.
12. Esser MJ, Sawynok J. Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur J Pharmacol. 2000;399:131-139.
13. Esser MJ, Sawynok J. Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. Pain. 1999;80:643-653.
14. Ulugol A, Karadag HC, Tamer M, Firat Z, Aslantas A, Dokmeci I. Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett. 2002;328:129-132.
15. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C III. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther. 1998;284:208-214.
16. Casis O, Sanchez-Chapula JA. Mechanism of block of cardiac transient outward K+ current (I(to)) by antidepressant drugs. J Cardiovasc Pharmacol. 1998;32:527-534.
17. Joshi PG, Singh A, Ravichandra B. High concentrations of tricyclic antidepressants increase intracellular Ca2+ in cultured neural cells. Neurochem Res. 1999;24:391-398.
18. Gray AM, Pache DM, Sewell RD. Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol. 1999;378:161-168.
19. Park TJ, Shin SY, Suh BC, et al. Differential inhibition of catecholamine secretion by amitriptyline through blockage of nicotinic receptors, sodium channels, and calcium channels in bovine adrenal chromaffin cells. Synapse. 1998;29:248-256.
20. Kelley BM, Porter JH. The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav. 1997;57:707-719.
21. Eisenach JC, Gebhart GF. Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology. 1995;83:1046-1054.
22. Traiffort E, Pollard H, Moreau J, et al. Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine. J Neurochem. 1992;59:290-299.
23. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev. 2003;55:1-20.
24. Gray AM, Spencer PS, Sewell RD. the involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol. 1998;124:669-674.
25. Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain. 1999;80:45-55.
26. Gerner P, Kao G, Srinivasa V, Narang S, Wang GK. Topical amitriptyline in healthy volunteers. Reg Anesth Pain Med. 2003;28:289-293.
27. Haderer A, Gerner P, Kao G, Srinivasa V, Wang GK. Cutaneous analgesia after transdermal application of amitriptyline versus lidocaine in rats. Anesth Analg. 2003;96:1707-1710.
28. Lynch ME, Clark AJ, Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain. 2003;19:323-328.
29. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103:140-146.
30. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain. 2008;24:51-55.
31. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
32. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19:833-841.
33. Ceschel G, Bergamante V, Maffei P, et al. Solubility and transdermal permeation properties of a dehydroepiandrosterone cyclodextrin complex from hydrophilic and lipophilic vehicles. Drug Deliv. 2005;12:275-280.
34. Lockhart E. Topical combination of amitriptyline and ketamine for post herpetic neuralgia. J Pain. 2004;5:S82 (abstract
35. Everton D, Bhagwat D, Damask M. A multicenter, double-blind, randomized, placebo controlled study of the efficacy/safety of two doses of amitriptyline/ketamine topical cream in treating post-herpetic neuralgia (PHN). J Pain. 2007;8:S47 (abstract
36. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain. 2005;6:644-649.
37. Moghadamnia AA, Partovi M, Mohammadianfar I, et al. Evaluation of the effect of locally administered amitriptyline gel as adjunct to local anesthetics in irreversible pulpitis pain. Indian J Dent Res. 2009;20:3-6.
38. Scott MA, Letrent KJ, Hager KL, Burch JL. Use of transdermal amitriptyline gel in a patient with chronic pain and depression. Pharmacotherapy. 1999;19:236-239.
39. Müller N, Brockmöller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. Ther Drug Monit. 1991;13:533-536.
40. Everton D, Bhagwat D, Damask M. An open-label pharmacokinetic study in humans of a 4% amitriptyline, 2% ketamine topical cream. J Pain. 2007;8:S48 (abstract
41. Benedetti MS, Whomsley R, Poggesi I, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41:344-390.
42. Tsai JC, Lin CY, Sheu HM, Lo YL, Huang YH. Noninvasive characterization of regional variation in drug transport into human stratum corneum in vivo. Pharm Res. 2003;20:632-638.
43. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175:265-275.
44. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996;64:293-302.
45. Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain. 1997;13:313-323.
46. Dualé C, Daveau J, Cardot JM, Boyer-Grand A, Schoeffler P, Dubray C. Cutaneous amitriptyline in human volunteers: differential effects on the components of sensory information. Anesthesiology. 2008;108:714-721.
47. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
48. McCleane G. Topical analgesics. Med Clin North Am. 2007;91:125-139.